Spyre Therapeutics Has Initiated Dosing Of Healthy Volunteers In Its First Clinical Trial Of SPY001 For Inflammatory Bowel Disease, Interim Subcutaneous Pharmacokinetic And Safety Data Anticipated By End Of 2024
Portfolio Pulse from Benzinga Newsdesk
Spyre Therapeutics has started dosing healthy volunteers in its first clinical trial of SPY001 for Inflammatory Bowel Disease. Interim pharmacokinetic and safety data are expected by the end of 2024. SPY002 is set to begin first-in-human studies in the second half of 2024. All three next-generation antibodies are on track to be in the clinic within 12 months.
June 18, 2024 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spyre Therapeutics has initiated dosing in its first clinical trial of SPY001 for Inflammatory Bowel Disease, with interim data expected by the end of 2024. SPY002 is also on track for human studies in the second half of 2024. This progress could positively impact the stock price.
The initiation of clinical trials and the expected interim data by the end of 2024 are significant milestones for Spyre Therapeutics. Additionally, the progress of SPY002 and other next-generation antibodies indicates a robust pipeline, which is likely to positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100